CDC study shows decreasing CLABSIs in hospitals

Some encouraging news came out of the CDC last week on CLABSI rates.  The CDC calculated the total central line days in the U.S. in 2001 and 2009 and estimated the total number of CLABSIs that occurred during the same time period.  The results showed a 58% CLABSI rate reduction from 2001 to 2009.  This reduction represents 25,000 fewer incidences of CLABSIs in 2009 than in 2001, and translates into 3,000-6,000 lives saved and $414 million of excess healthcare costs.  The reduction in CLABSIs was greatest for Staphylococcus aureus CLABSIs which showed a 73% reduction.   

 

The CDC credits this significant drop in CLABSI rates to collaborative efforts among federal, state, and regional agencies and cited a couple notable examples in the Pittsburgh Regional Healthcare Initiative (http://www.prhi.org/) and the Michigan Keystone Project (http://www.mhakeystonecenter.org/).  Both initiatives involve a combination of regional mandate on CLABSI reporting and broad dissemination of prevention education and best practices.  

Link to full report

CDC considers rule change for pricing of antibiotics

The annual number of antibiotics introduced to the market has been falling around the world. Between 2003 and 2007, only 5 new antibiotics were approved by the FDA in the US. In an effort to encourage the research and development of new antibiotics, the CDC launched a campaign on November 15th to stop the overuse of antibiotics. Key to the campaign is a proposed change in the pricing of these medicines. Currently, pharmaceutical companies have little incentive to develop new antibiotics because new antibiotics are likely to be used only sparingly at first in order to stave off the emergence of resistance. Conservative use of new antibiotics means less profit for the pharmaceutical company, which means it is unlikely to recoup the upfront investment within the fixed patent protection period.

The new solution proposed by the CDC would compensate companies for the true value of the antibiotic. Under the new proposal, new antibiotics will no longer be subjected to the traditional patent period; instead, payment for new antibiotics would be conditioned on meeting conservation and resistance targets set by the CDC. One example could be the rate of emerging resistance. If the company's antibiotic meets the target then it would maintain its market exclusivity. The government hopes that the proposed plan will give incentive to drug companies to develop new antibiotics under the new proposal.

The development of new antibiotics is important because there is an overwhelming number of outbreaks of hospital acquired infections, like MRSA, which could be controlled and treated with these drugs. Among the other diseases that could be targeted by new antibiotics are malaria, anthrax, and tularemia.

New York Times article
Boston Global article